The Committee for Medicinal Products for Human Use (CHMP) recommended expansion of the Carvykti label to include adult patients with relapsed and refractory multiple myeloma, who have received at ...

New innovative local treatment for osteolytic bone disease in multiple myeloma. ScienceDaily . Retrieved February 11, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250114125014.htm ...

The research team envisions sicXer and boXer as components of a novel combined systemic and local treatment strategy for multiple myeloma. Beyond oncology, these materials may have applications in ...

Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.

People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...